Later, on 1 September 2017, the U.S. Food and Drug Administration approved GO (Mylotarg, Pfizer) for the treatment of relapsed or refractory (R/R) CD33-positive AML in adults as a monotherapy, as well as for newly diagnosed CD33-positive AML in adults and pediatric patients 1 month and older in combination with chemotherapy. The gene discussed is CD33; the disease is acute myeloid leukemia.